Document is current
Any future updates will be listed below
-
Authors
Schwede, Matthew https://orcid.org/0000-0002-0778-9230
Jahn, Katharina
Kuipers, Jack https://orcid.org/0000-0001-5357-2705
Miles, Linde A.
Bowman, Robert L.
Robinson, Troy
Furudate, Ken https://orcid.org/0000-0003-1272-5490
Uryu, Hidetaka https://orcid.org/0000-0001-7167-895X
Tanaka, Tomoyuki
Sasaki, Yuya https://orcid.org/0000-0001-8232-0910
Ediriwickrema, Asiri https://orcid.org/0000-0002-6480-8290
Benard, Brooks https://orcid.org/0000-0001-7154-744X
Gentles, Andrew J. https://orcid.org/0000-0002-0941-9858
Levine, Ross https://orcid.org/0000-0002-7884-1905
Beerenwinkel, Niko
Takahashi, Koichi https://orcid.org/0000-0002-8027-9659
Majeti, Ravindra https://orcid.org/0000-0002-5814-0984
- License Information
-
More Information
Article History
Received: 30 October 2023
Revised: 23 February 2024
Accepted: 28 February 2024
First Online: 11 March 2024
Competing interests
: LAM has received honoraria from Mission Bio and has served on their Speakers’ Bureau (2020-2021). RM is on the Advisory Boards of Kodikaz Therapeutic Solutions, Orbital Therapeutics, Pheast Therapeutics, and 858 Therapeutics. RM is a co-founder and equity holder of Pheast Therapeutics, MyeloGene, and Orbital Therapeutics. RLL is on the supervisory board of QIAGEN and is a scientific advisor to Imago, Mission Bio, Syndax, Zentalis, Ajax, Bakx, Auron, Prelude, C4 Therapeutics, and Isoplexis for which he receives equity support. RLL receives research support from Ajax and Abbvie and has consulted for Incyte, Janssen, Morphosys, and Novartis. RLL has received honoraria from Astra Zeneca and Kura for invited lectures and from Gilead for grant reviews. KT has received honoraria from Mission Bio and Illumina Inc. and received scientific advisory fees from Symbio Pharmaceuticals.
